Haussier
Johnson & Johnson's OTTAVA robotic surgery system receives FDA approval, shares rise 2%
Ce briefing n’est pas encore disponible dans cette langue — version anglaise affichée.
Johnson & Johnson's stock rose 2% following the FDA's approval of its OTTAVA robotic surgery system, marking a significant expansion into the surgical robotics market. Analysts have responded positively, with several firms raising price targets and issuing buy ratings. The company also reported solid fundamentals, including better-than-expected quarterly earnings and an increased dividend.
Points clés
- FDA grants marketing authorization for OTTAVA robotic surgery system, expanding J&J's presence in surgical robotics.
- Analysts raise price targets and issue buy ratings following the OTTAVA approval.
- J&J reports strong quarterly earnings, beats EPS and revenue estimates, and raises full-year guidance.
- Company increases quarterly dividend to $1.34 per share, enhancing appeal to income-focused investors.
Sources
- Johnson & Johnson (NYSE:JNJ) Shares Up 2% - Here's WhyMarketBeat · July 22, 2026
- Johnson & Johnson (NYSE:JNJ) Sets New 52-Week High - Still a Buy?MarketBeat · July 2, 2026
- Johnson & Johnson declares $1.34 quarterly dividendInvesting.com · July 15, 2026
- Johnson & Johnson beats estimates but shares dipInvesting.com · July 15, 2026
Généré par IA à partir de sources d'actualités publiques. Ceci n'est pas un conseil financier.
